, including people who may not have needed it such as those with false positive results Repeat testing / additional testing Secondary accuracy outcomes: Sensitivity / specificity and other test accuracy measures 5 Intervention In people with heart failure what is the clinical and cost effectiveness of cardiac MRI followed by the appropriate patient pathway? Critical outcomes: All-cause mortality (time to event) Health-related quality of life at 12 months (continuous) Unplanned hospitalisation (total number of events (rate ratio)) Important outcomes: Adverse events related to test (non-specific fibrosis in the presence of renal dysfunction) Reclassification of specific HF aetiology (including ability to classify previous unclassified patients) Change in management HF medication use HF advanced therapy use, including disease specific therapies Repeat testing / additional testing 6 Intervention What is the clinical and cost effectiveness of salt and/or fluid restriction in people with heart failure? Critical outcomes: Quality of life at 12 months (Continuous) Unplanned hospitalization (Count rate) Important outcomes: Change in weight at 12 months Chronic Heart Failure Methods NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Chapter Type of review Review questions Outcomes (Continuous) Change in oedema at 12 months (Continuous) Change in sodium level (Continuous)(in the low baseline sodium strata only) Adverse events - Renal function at 12 months (Dichotomous) Adverse events - Hyperkalaemia at 12 months (Dichotomous) 6 Intervention What is the clinical and cost effectiveness of beta-blockers in the management of chronic heart failure in people with heart failure with reduced ejection fraction (HFREF) and atrial fibrillation? Critical outcomes: All-cause mortality Health-related quality of life Unplanned hospitalisation Important outcomes: Other adverse events (stroke, bradycardia, hypotension) Improvement of NYHA class 6 Intervention What is the clinical and cost effectiveness of mineralocorticoid receptor antagonists in people with heart failure with preserved ejection fraction? 